North America Biosensors Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

North America Biosensors Market Size

• The North America Biosensors market was valued at USD 710.29 million in 2025 and is expected to reach USD 1,222.81 million by 2033, growing with a substantial CAGR of 7.6% in the forecast period of 2026 to 2033.
• The market is primarily driven by the rising demand for rapid, cost-effective, and highly sensitive diagnostic and bioprocess monitoring solutions. Key adoption areas include point-of-care testing, continuous glucose monitoring, cell and gene therapy process monitoring, and real-time biomanufacturing analytics across clinical, research, and pharmaceutical settings.
• Sustained market expansion is supported by ongoing advancements in microfluidics, AI-enabled biosensing, wearable biosensors, and integrated digital health platforms, along with increasing availability of connected monitoring systems. Favorable regulatory support, growing investments in precision medicine and advanced therapeutics, and the increasing emphasis on early disease detection, process optimization, and personalized healthcare are strengthening the overall market outlook in North America.

North America Biosensors Market Analysis

• The North America Biosensors market is witnessing steady advancement as solution providers increasingly focus on technological innovation, bioprocess efficiency, and application-specific optimization to address evolving clinical and biomanufacturing requirements. Biosensor developers are leveraging microfluidics, AI-driven analytics, IoT-enabled sensing platforms, and advanced automation systems to enhance real-time monitoring, process control, biomarker detection, and quality assurance across cell and gene therapy workflows, pharmaceutical manufacturing, and clinical diagnostics. Integration of digital dashboards, real-time data connectivity, and cloud-based analytics platforms is further shaping product development strategies across the region.
• These advancements are strengthening the regional biosensors value chain by improving operational efficiency, scalability, and decision accuracy while reducing batch failures, manual intervention, and overall manufacturing costs. Expanding direct sales channels, distributor networks, strategic partnerships with biopharma companies, and collaborations with contract development and manufacturing organizations (CDMOs) are enabling faster market penetration and improved end-user access. Rising adoption of biosensor solutions across cell therapy production, gene therapy analytics, point-of-care diagnostics, and continuous bioprocess monitoring—supported by favorable regulatory frameworks, innovation funding, and advanced therapy initiatives—is further enhancing market accessibility.
• S. dominated the North America biosensors market with the largest revenue share of 81.41% in 2026, supported by its strong biopharmaceutical manufacturing base, advanced research infrastructure, high adoption of process analytical technologies, and sustained investments in cell and gene therapy development and precision diagnostics.
• The Canada is projected to be the fastest-growing market, registering a CAGR of 8.4%, driven by expanding advanced therapy pipelines, increasing adoption of real-time bioprocess monitoring, strong academic–industry collaborations, and supportive government initiatives promoting life sciences innovation and digital health integration.
• In 2025, the Biosensors for Cell Therapies segment dominated the North America biosensors market with a 70.28% share, reflecting strong demand for real-time cell culture monitoring, metabolite sensing, viability assessment, and closed-loop bioprocess control solutions. Widespread use across cell manufacturing workflows, quality control, and process optimization—combined with continuous technological innovation and digital integration—continues to reinforce the segment’s leadership within the North America Biosensors market.

Report Scope in North America Biosensors Market Segmentation

 North America Biosensors Market Trends

“Integration With Closed and Automated CGT Manufacturing Platforms”

• Integration of advanced biosensors into closed and automated cell and gene therapy (CGT) manufacturing platforms represents a strategic opportunity to accelerate process development, enhance product quality, and enable scalable production. Automated platforms that embed biosensor data into live control systems reduce reliance on manual sampling, improve reproducibility, and support real‑time closed‑loop process control—a critical requirement for high‑value biologics and CGT products.
• Several companies from the biosensor and bioprocessing ecosystem have publicly highlighted press release collaborations and product innovations that align with this trend:
• In January 2026, Cytiva’s automation collaborations for CGT manufacturing: Cytiva entered a collaboration with Cellular Origins to combine its automated Sefia manufacturing technologies with Cellular Origins' Constellation robotic platform. The two systems are engineered to interface seamlessly for fully automated CGT production, including digital controls, analytics, and digital interconnection across quality systems, removing the need for manual intervention during critical manufacturing steps. GMP‑ready systems are anticipated by late 2025.
• In May 2024, Sartorius announced an expanded collaboration with NVIDIA to integrate advanced AI and predictive analytics into life‑science instruments and manufacturing tools. Although the press release focuses on drug discovery, the integrated use of AI‑driven analytics within bioprocessing workflows points to increased integration of data‑centric sensing, predictive models, and process automation within future CGT manufacturing setups
• In summary, these company press releases underscore a clear industry movement toward biosensor integration within automated, information rich manufacturing environments. By enabling continuous, automated sampling, analysis, and control, biosensors are poised to become core components of closed CGT production workflows, supporting enhanced process control, reduced operator burden, and improved product quality—all of which are key drivers of wider adoption and market expansion in the biopharmaceutical and cell and gene therapy manufacturing sectors.

North America Biosensors Market Dynamics

Driver

“Shift Toward Real-Time and Continuous Bioprocess Monitoring”

• The North America biosensor market for Cell and Gene Therapy (CGT) is undergoing a fundamental transformation, moving away from labor-intensive offline sampling toward Real-Time and Continuous Bioprocess Monitoring. Historically, CGT manufacturing relied on discrete "grab-sampling," where media was manually extracted and sent to a lab for analysis—a process that introduces contamination risks and "dead time" where critical deviations can occur unnoticed.
• As of 2026, the industry is adopting Process Analytical Technology (PAT) to achieve "Pharma 4.0" standards, where biosensors are integrated directly into closed-loop systems to provide instantaneous feedback on cell health and metabolic activity.
• The demand for real-time monitoring is fueled by the need to reduce the high cost of goods (COGS) in CGT, where a single failed batch of CAR-T cells can represent a loss of USD 300,000 to USD 500,000 in manufacturing costs alone. Government regulatory bodies, led by the U.S. FDA, have issued specific guidance to encourage the adoption of continuous monitoring to ensure product safety and "Quality by Design" (QbD)
• In December 2025, the FDA released final guidance on "Processes and Practices Applicable to Bioresearch Monitoring Inspections". This guidance emphasizes the importance of data integrity and the use of automated, real-time records to replace error-prone manual logs.
• In June 2025, the UK government opened Digital and Automation Testbeds specifically designed to help CGT manufacturers integrate real-time biosensors into automated manufacturing workflows to increase global patient access.
• The shift toward continuous monitoring allows for closed-loop control, where the biosensor detects a nutrient drop and automatically triggers the bioreactor to feed the cells. This reduces human error—a factor responsible for roughly 50% of batch deviations in personalized medicine—and ensures that every dose of gene therapy meets the exact potency requirements for the patient.

Restraints/Challenges

“Limited Sensitivity and Cross-Reactivity Issues”

• A significant restraint on the growth of the global biosensor market—especially for cell and gene therapy (CGT) applications—is the persistent challenge in achieving high analytical sensitivity and avoiding cross‑reactivity in complex biological environments. Biosensors used in CGT settings (e.g., real‑time monitoring of therapeutic vectors, immune biomarkers, or minimal residual disease) must reliably detect ultra‑low analyte concentrations and discriminate target molecules from a milieu of similar substances. However, many current technologies demonstrate performance gaps, leading to false positives and false negatives, increasing reliance on confirmatory laboratory assays and slowing clinical adoption.
• In complex samples such as blood or plasma, matrix effects and nonspecific interactions can degrade signal fidelity, inhibiting accurate target detection and diminishing sensitivity. Studies note that serum components can almost completely inhibit reporter production (>98%) in cell‑free biosensing systems, evidencing how real samples can suppress intended assay signals. 
• In March 2023, The U.S. Food and Drug Administration (FDA) issued a Class I recall of ~2.7 million lateral‑flow biosensor kits after buffer contamination was found to potentially impact test performance and produce inaccurate results (false positives/negatives), underscoring how sensitivity and signal integrity issues can lead to major product actions.
• In the development of their ATHENA capsid platform, AAVnerGene must manage the fact that different AAV serotypes (e.g., AAV1, AAV6, and AAV10) share 60–90% sequence identity.
• In January 2024, an article was published on PNAS, A major limitation in metabolic biosensors has been the cross-reactivity between aspartate and glutamate. Researchers developed jAspSnFR3, a fluorescent biosensor specifically for aspartate. By introducing two point mutations (S27A and S72P) into the binding domain, they rendered the sensor highly specific for Asp while making it completely insensitive to glutamate. This optimization provided excellent discrimination against other analytes with affinities ranging from 4uM to 500 uM, allowing for real-time imaging of previously "un-trackable" nutrient dynamics.
• Limited sensitivity and cross‑reactivity remain critical restraints on the global biosensor market, particularly in cell and gene therapy applications. These technical challenges compromise the accuracy and reliability of biosensors in complex biological matrices, necessitating confirmatory testing and slowing clinical adoption. Real-world examples—from FDA recalls of contaminated rapid tests to the need for serotype-specific monitoring in AAV platforms—highlight the tangible impact on product performance and regulatory compliance. While innovative solutions, such as engineered point mutations in metabolic biosensors (e.g., jAspSnFR3), demonstrate that specificity improvements are achievable, these issues continue to restrict market growth and underscore the need for further technological advancements in sensitivity, selectivity, and real-time detection capabilities

North America Biosensors Market Scope

North America biosensors market is categorized into two notable segments which are based on therapy modality, and analytical sensor.

• By Therapy Modality

On the basis of therapy modality, the North America biosensors market is segmented into biosensors for cell therapies and biosensors for gene therapies.

In 2026, the biosensors for cell therapies segment is expected to dominate the market with a 70.45% share, driven by the expanding commercialization of cell-based therapies and the growing need for real-time, high-precision bioprocess monitoring. Increasing deployment across cell therapy manufacturing workflows—including cell culture monitoring, metabolite sensing, and viability assessment—along with strong investments in advanced therapy medicinal products (ATMPs), continues to reinforce the segment’s leadership in the region.

The biosensors for cell therapies segment is expected to be the fastest-growing, registering a CAGR of 7.9% in the North America biosensors market. Growth is driven by rising demand for closed-loop process control, scalable manufacturing platforms, and automated quality monitoring systems that enable data-driven bioprocess optimization and regulatory compliance. Increasing adoption among biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), and research institutes—along with expanding integration of cloud connectivity, digital twins, and AI-enabled analytics—is expected to further accelerate market penetration across North America.

• By Analytical Sensor

On the basis of analytical sensor, the North America biosensors market is segmented into upstream bioprocess monitoring, downstream processing & purification analytics, critical quality attribute (CQA) monitoring, and potency & functional activity assays.

In 2026, the upstream bioprocess monitoring segment is expected to dominate the market with a 44.01% share, driven by its critical role in real-time cell culture monitoring, metabolite tracking, and process optimization during early-stage biomanufacturing. Strong adoption across biopharmaceutical manufacturers, cell and gene therapy developers, and CDMOs supported by the need to reduce batch failures, improve yield consistency, and enable scalable closed-system production—continues to reinforce the segment’s leadership in North America.

The critical quality attribute (CQA) monitoring segment is expected to be the fastest-growing, registering a CAGR of 8.2% in the North America Biosensors market. Growth is driven by increasing regulatory emphasis on product quality, comparability, and real-time release testing for advanced therapies. Rising demand for high-sensitivity biosensors that enable continuous monitoring of potency, purity, identity, and safety attributes combined with expanding adoption of process analytical technology (PAT), AI-enabled analytics, and digital biomanufacturing platforms is expected to further accelerate market expansion across the North America region.

North America Biosensor Market Regional Analysis

• The North America biosensors market is witnessing consistent growth, supported by increasing investments in biopharmaceutical research, precision medicine, and advanced diagnostic technologies across the region. Expanding government initiatives to strengthen healthcare infrastructure, rising focus on biomanufacturing capabilities, and growing adoption of cell and gene therapy development are accelerating market expansion. In addition, the integration of real-time monitoring systems, microfluidics, IoT-connected biosensors, and laboratory automation technologies is enhancing process optimization, quality control, and regulatory compliance.
• The U.S. biosensors market is experiencing steady growth, driven by the country’s expanding focus on advanced biomanufacturing, precision diagnostics, and cell and gene therapy development. Strong government support for life sciences innovation, rising investments in biopharmaceutical R&D, and modernization of laboratory and manufacturing infrastructure are improving adoption rates. Additionally, the growing use of real-time analytics, microfluidic platforms, IoT-enabled biosensing systems, and automation technologies continues to strengthen U.S. position within the North America Biosensors market—particularly in addressing process efficiency, product quality assurance, and regulatory compliance in advanced therapy production.

Canada Biosensors Market Insight

The Canada biosensors market is expected to expand steadily, supported by increasing emphasis on biopharmaceutical productivity, advanced therapy development, and digital transformation in life sciences. Rising adoption of real-time bioprocess monitoring, process analytical technologies (PAT), and high-sensitivity diagnostic biosensors—along with expanding access through collaborations between biopharma companies, research institutes, and CDMOs—is supporting market development. Furthermore, growing demand for cost-effective, scalable, and easy-to-integrate biosensor platforms is driving sustained adoption across both clinical research and commercial manufacturing environments, particularly in cell and gene therapy workflows and precision medicine.

Mexico Biosensor Market Insight

The Mexico biosensors market is gradually expanding, supported by the country’s growing emphasis on healthcare innovation, biomedical research, and advanced diagnostic capabilities. Increasing investments in life sciences, alongside improvements in laboratory infrastructure and pharmaceutical manufacturing, are contributing to higher adoption of biosensing technologies. The market is also benefiting from the rising demand for rapid disease detection, real-time monitoring solutions, and automated analytical systems across healthcare and research institutions.

The Major Market Leaders Operating in the Market Are:

• PreSens Precision Sensing GmbH (Germany)
• ABSELION (U.K.)
• PROGEN (Germany)
• Aber Instruments Ltd (U.K.)
• Cytiva (U.S.)
• ABBOTT LABORATORIES (U.S.)
• BIO-RAD LABORATORIES (U.S.)
• Myriade (France)
• Unchained Labs (U.S.)
• IST AG (Switzerland)
• Nova Biomedical (U.S.)
• YSI Inc. (part of Xylem Inc.) (U.S.)
• NANOENTEK INC. (South Korea)
• ROCHE DIAGNOSTICS (Switzerland)
• AAVnerGene (U.S.)
• Genemedi (China)
• Montana Molecular (U.S.)
• ProAnalytics, LLC (U.S.)
• Universal Biosensors (Australia)
• Sartorius AG (Germany)
• Agilent Technologies, Inc. (U.S.)
• Hillgene Biopharma Co., Ltd. (China)
• Sphere Bio - A Fluidic Sciences Ltd Brand (U.K.)
• ChemoMetec (Denmark)
• Nicoya Lifesciences Inc. (Canada)
• Flownamics (U.S.)
• NanoTemper Technologies (Germany)
• Refeyn Ltd. (U.S.)
• Hamilton company (U.S.)
• Palmsence (Netherlands)
• Evrogen (Russia)
• Creative-biolabs (U.S.)
• Dynamic-biosensors (Germany)
• Quantum biosciences (U.S.)
• Merck KGaA (Germany)

Latest Developments in North America Biosensors

• In May 2025, Sartorius AG announced the launch of the Octet R8e biolayer interferometry (BLI) system, expanding its label-free biomolecular analysis portfolio. The new platform delivers enhanced sensitivity and broader dynamic range, enabling accurate detection of low-molecular-weight and low-abundance analytes for complex biologics workflows. It supports both 96- and 384-well plate formats with sample volumes as low as 40 µL, improving throughput and cost efficiency. The system also incorporates advanced evaporation control for up to 16-hour runtimes, positioning the Octet R8e as a high-performance solution for drug discovery, process development, and biopharmaceutical research.
• In March 2025, Agilent Technologies announced that its xCELLigence Real-Time Cell Analysis (RTCA) platform was applied in support of the FDA approval of the CAR-T therapy AUCATZYL by Autolus Therapeutics. The RTCA technology was used to develop and validate a label-free potency assay, enabling precise real-time monitoring of cell activity critical for regulatory submission. The platform delivers continuous, impedance-based measurements that improve assay robustness and reproducibility. Its successful use in the approval process highlights the growing role of RTCA systems in cell therapy development and quality control workflows.
• In July 2025, Bio Rad Laboratories has broadened its digital PCR offerings by launching four new Droplet Digital PCR (ddPCR) platforms, including the new QX Continuum system and three models in the QX700 series, expanding its genomics research and clinical diagnostics lineup with advanced multiplexing, high throughput and streamlined workflows. This expansion strengthens Bio Rad’s position in the competitive ddPCR market and enhances its appeal to research and clinical labs, likely helping drive future sales growth.
• In May 2024, Abbott’s GLP systems Track, an innovative lab automation solution designed to support high volume analytical workflows, has been launched to help clinical and research laboratories increase throughput and reduce manual handling. The system offers scalable automation with flexible track design and intelligent sample transport. This launch strengthens Abbott’s diagnostics infrastructure and supports complex analytical processes conceptually relevant to CQA monitoring and high volume workflows like those in cell & gene therapy manufacturing

SKU-16335